AtG Therapeutics: Rewriting the Future of Cancer Treatment
10 FINALIST - II Entrepreneurship Call 2025: Women in Technology
When we talk about innovation, we often imagine new devices, futuristic labs, or complex algorithms. But sometimes, true innovation begins somewhere quieter in the shared conviction of a team that refuses to accept that things “are the way they are.”
AtG Therapeutics was born from that refusal.
Founded in Spain by Oriol Casanovas, PhD, and Gabriela Jiménez, PhD, AtG emerged with one bold idea: What if we could outsmart cancer at its smartest moment?
Not when it first appears.
Not when it grows.
But at the exact point where it adapts when the disease learns to resist treatments and evade the body’s defenses.
This is the moment where so many therapies fail. And this is exactly where AtG decided to begin.
AtG team members
A New Way of Seeing Cancer
Cancer is not just a disease; it’s a strategist. It shifts. It evolves. It learns how to survive.
AtG Therapeutics chose to confront this challenge head-on by targeting the heart of this adaptability. Their research led them to TA-1, a molecular mechanism essential for tumor survival, especially when cancer is under stress such as during treatment.
Instead of trying to attack the tumor from familiar angles, they developed a therapeutic approach aimed at this hidden vulnerability. Their lead compound, tested in advanced preclinical studies, has already shown remarkable promise.
Where traditional therapies hit a wall, AtG aims to open a new door.
Science with Humanity at Its Center
What makes AtG stand out is not only its scientific ambition, but its human one.
Behind the technology lies a diverse and deeply committed team researchers, innovators, clinicians, and advisors from around the world all driven by a shared mission: to offer hope where current treatments fall short.
Their work is grounded not only in molecular precision but in emotional understanding. Every breakthrough, every experiment, every model tested is tied to a real person who is waiting for better options, more time, or simply a second chance.
AtG Therapeutics is pursuing that chance for them.
Building a Future That Doesn’t Settle
Their approach is also deeply forward-looking.
The same platform that powers AtG’s cancer research a sophisticated ecosystem of models, predictive tools, and biomarkers has the potential to transform the discovery of therapies across oncology.
What begins with kidney and colon cancer could expand to many other tumors. What starts as one treatment could become a new therapeutic class altogether.
This is not incremental progress.
This is paradigm-shifting science.
Why Their Work Matters
Cancer is a story that touches nearly every family. It disrupts lives, tests resilience, and pushes science to its limits. But AtG is moving those limits. They are not only developing a therapy — they are changing the narrative around how we confront the disease.
They represent a future where:
resistance is not the end of the road
treatments grow smarter as tumors grow tougher
and innovation becomes a force of compassion as much as science
This is the kind of work that reshapes an industry and deeply impacts society.
We are proud to celebrate AtG Therapeutics, awarded fifth place in the Women in Technology II Entrepreneurship Call 2025 by Tara for Women.
Congratulations to the team your groundbreaking work, passion, and commitment to innovation inspire us, and we look forward to seeing the positive impact your journey will make in the world of oncology and beyond!